Eve-Marie Thillard1*Sophie Gautier2Evgeniya Babykina1Louise Carton3Ali Amad4Guillaume Bouzillé5Jean-Baptiste Beuscart1Emmanuel Chazard1- 1Univ. Lille, CHU Lille, ULR 2694, CERIM, Public Health Department, Lille, France
- 2Univ. Lille, Inserm, CHU Lille, UMR-S1172, Center for Pharmacovigilance, Lille, France
- 3Univ. Lille, Inserm, CHU Lille, UMR_S1172, Medical Pharmacology Department, Lille, France
- 4Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France
- 5University of Rennes, Inserm, CHU Rennes, UMR 1099 - LTSI, Rennes, France
A Correction on
Psychiatric adverse events associated with infliximab: a cohort study from the French nationwide discharge abstract database
by Thillard E-M, Gautier S, Babykina E, Carton L, Amad A, Bouzillé G, Beuscart J-B and Chazard E (2020). Front. Pharmacol. 11:513. doi: 10.3389/fphar.2020.00513
Author Grégoire Ficheur was erroneously included as an author in the published article. The correct author list reads:
Eve-Marie Thillard, Sophie Gautier, Evgeniya Babykina, Louise Carton, Ali Amad, Guillaume Bouzillé, Jean-Baptiste Beuscart and Emmanuel Chazard.
The Author Contributions Statement has been corrected to read:
E-MT performed the study, analyzed the data, drafted the manuscript, and revised the manuscript. SG supervised the work (especially with regard to pharmacology), and critically revised the manuscript. EB supervised the work (especially with regard to statistics), and critically revised the manuscript. LC gave advice on the psychiatric events and pharmacology, and critically revised the manuscript. AA gave advice on the psychiatric events, and critically revised the manuscript. GB and J-BB gave advice on medical and methodological aspects of the work, and critically revised the manuscript. EC designed the study, managed, and extracted the data, supervised the study and the analysis, drafted the manuscript, and revised the manuscript. All the authors agree to be accountable for all aspects of the work, and provide approval for publication of the content.
The original article has been updated
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: infliximab, adverse events, psychiatry, depression, database, pharmacoepidemiology, pharmacovigilance
Citation: Thillard E-M, Gautier S, Babykina E, Carton L, Amad A, Bouzillé G, Beuscart J-B and Chazard E (2025) Correction: Psychiatric adverse events associated with infliximab: a cohort study from the French nationwide discharge abstract database. Front. Pharmacol. 16:1719490. doi: 10.3389/fphar.2025.1719490
Received: 06 October 2025; Accepted: 07 October 2025;
Published: 22 October 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Thillard, Gautier, Babykina, Carton, Amad, Bouzillé, Beuscart and Chazard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eve-Marie Thillard, ZXZlbWFyaWUudGhpbGxhcmRAZ21haWwuY29t